凝血因子缺乏症市場規模、佔有率和成長分析：按因子類型、治療方法、通路、最終用戶和地區分類－2026-2033年產業預測

2024 年全球凝血因子缺乏症市場價值為 145.2 億美元，預計到 2033 年將從 2025 年的 154.8 億美元成長至 258.5 億美元，預測期（2026-2033 年）複合年成長率為 6.62%。

由於遺傳性出血性疾病盛行率上升以及重組療法的日益普及，凝血因子缺乏症治療市場正經歷顯著成長。基因治療研究投資的激增和個人化醫療的進步也推動了這一成長趨勢。對更安全療法和創新治療方案的需求也是市場成長的驅動力。半衰期延長的療法和基因編輯技術的應用提高了治療效果，加上對生物技術和專業設施的投資，進一步促進了市場成長。此外，新療法的健保覆蓋範圍擴大也為全球市場創造了新的機會。然而，高昂的治療費用、某些地區先進療法的可及性有限以及嚴格的監管障礙等挑戰可能會阻礙市場滲透。

全球凝血因子缺乏症市場按因子類型、治療方法、分銷管道、最終用戶和地區進行細分。依因子類型分類，市場分為因子VIII（A型血友病）、因子IX（B型血友病）、因子VII及血管性血友病因子。依治療方法分類，市場分為重組因子製劑、血漿衍生製劑及非因子療法（如艾美賽珠單抗）。依通路分類，市場分為醫院藥房和專科藥房。依最終用戶分類，市場分為血友病治療中心和醫院。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球凝血因子缺乏症市場的成長要素

重組凝血因子的供應增加，以及其安全性提高和保存期限延長，顯著降低了對血漿衍生產品的依賴。這些重組因子因其感染疾病傳播風險較低、劑量調整更精準而備受醫療專業人員青睞，最終有助於提高患者的治療依從性。因此，醫療專業人員擴大使用這些重組療法，推動了成熟市場和新興市場的需求成長。這一趨勢凸顯了凝血因子缺乏症患者治療方案朝向更安全、更有效方向的重大轉變。

全球凝血因子缺乏症市場的限制因素

全球凝血因子缺乏症治療市場面臨一項重大挑戰：凝血因子濃縮劑高成本。這給患者、保險公司和國家醫療保健系統都帶來了障礙，尤其是在低收入地區。嚴格的報銷政策進一步阻礙了病患的就醫，其極為嚴苛的報銷條件使得病患難以實施有效的治療方案。醫療服務提供者優先考慮成本效益高的解決方案，從而限制了能夠改善患者預後的必要療法的應用。這種經濟負擔是先進療法引入醫療保健系統的主要障礙，使得患者難以獲得所需的治療。

全球凝血因子缺乏症市場趨勢

全球凝血因子缺乏症市場正經歷著向創新療法的轉型，這主要得益於基因治療和基因編輯技術的進步。這一趨勢標誌著傳統蛋白質替代療法的突破，各公司正積極探索利用病毒載體和基於CRISPR的系統來根治性A型和B型血友病。生技公司與研究機構之間日益密切的合作正在建立一個強大的產品開發平臺，旨在實現缺乏因子的持續表達。隨著細胞療法法律規範的不斷完善，相關人員對這些開創性策略充滿信心，並期待它們能顯著減輕患者的治療負擔。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系圖譜
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球凝血因子缺乏症市場規模：依凝血因子類型分類

• 因子VIII（A型血友病）
• 因子IX（B型血友病）
• 因子VII
• 血管性血友病因子

全球凝血因子缺乏症市場規模：依治療方式分類

• 重組凝血因子製劑
• 血漿衍生產品
• 非因子治療（emisizumab）

全球凝血因子缺乏症市場規模：依通路分類

• 醫院藥房
• 專科藥房

全球凝血因子缺乏症市場規模：依最終用戶分類

• 血友病治療中心
• 醫院

全球凝血因子缺乏症市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Roche（Hemlibra/Emicizumab）
• Sanofi（Altuviiio）
• Pfizer Inc.
• BioMarin Pharmaceutical
• Spark Therapeutics（Roche）
• Takeda Pharmaceutical（Advate）
• CSL Behring
• Grifols SA
• Novo Nordisk
• Biogen Inc.
• Bayer AG
• Octapharma
• Kedrion Biopharma
• Shire（Takeda）
• uniQure NV
• Sangamo Therapeutics
• CRISPR Therapeutics
• Freeline Therapeutics
• Ultragenyx Pharmaceutical
• Sorrento Therapeutics

結論與建議

Global Coagulation Factor Deficiency Market size was valued at USD 14.52 Billion in 2024 and is poised to grow from USD 15.48 Billion in 2025 to USD 25.85 Billion by 2033, growing at a CAGR of 6.62% during the forecast period (2026-2033).

The market for coagulation factor deficiency treatments is experiencing significant growth due to the rising prevalence of inherited bleeding disorders and the increased adoption of recombinant therapies. A surge in investments towards gene therapy research, along with advancements in personalized medicine, contribute to this upward trend. Demand for safe therapies and innovative treatment options is also driving the market. The application of prolonged-half-life treatments and gene editing techniques enhances therapeutic outcomes, while investments in biotechnology and specialized centers further stimulate growth. Additionally, improved reimbursement coverage for novel therapies creates opportunities in the global market. However, challenges such as high treatment costs, limited access to advanced therapies in certain regions, and stringent regulatory hurdles may hinder market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Coagulation Factor Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Coagulation Factor Deficiency Market Segments Analysis

Global coagulation factor deficiency market is segmented by factor type, treatment, distribution channel, end-user, and region. Based on factor type, the market is segmented into Factor VIII (Hemophilia A), Factor IX (Hemophilia B), Factor VII, and von Willebrand Factor. Based on treatment, the market is segmented into recombinant factor products, plasma-derived products, and non-factor therapies (Emicizumab). Based on distribution channel, the market is segmented into hospital pharmacies and specialty pharmacies. Based on end-user, the market is segmented into hemophilia treatment centers and hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Coagulation Factor Deficiency Market

The increasing availability of recombinant coagulation factors has significantly reduced the reliance on plasma-derived products, thanks to their enhanced safety profiles and longer shelf lives. These recombinant factors are particularly preferred by healthcare professionals due to their lower risk of disease transmission and more precise dosing, which ultimately contributes to improved patient compliance. As a result, healthcare practitioners are more inclined to prescribe these recombinant therapies, driving up demand in both established and developing markets. This trend highlights a pivotal shift towards safer, more effective treatment options for individuals with coagulation factor deficiencies.

Restraints in the Global Coagulation Factor Deficiency Market

The Global Coagulation Factor Deficiency market faces significant challenges primarily due to the high costs associated with factor concentrates, which pose barriers for patients, payers, and national health systems, especially in lower-income regions. Stringent reimbursement policies further complicate access, as the criteria can be so restrictive that patients struggle to implement effective treatment plans. Healthcare providers prioritize cost-effective solutions, limiting the adoption of necessary therapies that could improve patient outcomes. This financial burden creates substantial obstacles to the integration of advanced treatment options within the healthcare system, making it difficult for patients to receive the care they need.

Market Trends of the Global Coagulation Factor Deficiency Market

The Global Coagulation Factor Deficiency market is witnessing a transformative shift towards innovative treatment approaches, predominantly driven by advancements in gene therapy and gene-editing technologies. This trend marks a move away from traditional protein replacement therapies, as companies actively explore curative options for hemophilia A and B utilizing viral vectors and CRISPR-based systems. Enhanced collaborations between biotechnology firms and research organizations are fostering robust product development pipelines, aiming for sustained expression of deficient factors. As regulatory frameworks surrounding cell-based therapies evolve, stakeholders are optimistic about these pioneering strategies that promise to significantly reduce the treatment burden for patients.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Coagulation Factor Deficiency Market Size by Factor Type & CAGR (2026-2033)

• Market Overview
• Factor VIII (Hemophilia A)
• Factor IX (Hemophilia B)
• Factor VII
• von Willebrand Factor

Global Coagulation Factor Deficiency Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Recombinant Factor Products
• Plasma-Derived Products
• Non-Factor Therapies (Emicizumab)

Global Coagulation Factor Deficiency Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Coagulation Factor Deficiency Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hemophilia Treatment Centers
• Hospitals

Global Coagulation Factor Deficiency Market Size & CAGR (2026-2033)

• North America (Factor Type, Treatment, Distribution, End-User)
  • US
  • Canada
• Europe (Factor Type, Treatment, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Factor Type, Treatment, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Factor Type, Treatment, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Factor Type, Treatment, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche (Hemlibra/Emicizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (Altuviiio)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spark Therapeutics (Roche)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Advate)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Takeda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• uniQure NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freeline Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultragenyx Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations